Breaking oncology wire: Landmark 3-year Phase 2 trial results for personalized mRNA neoantigen vaccine in pancreatic ductal adenocarcinoma (PDAC). 84% sustained T-cell response.
Breaking cardiology wire: Bempedoic Acid outcomes in 13,970 statin-intolerant patients. Hepatic ACL targeting cuts MACE by 15% and heart attacks by 23% without myalgia.
Breaking Phase 2 trial results for VERVE-102 in-vivo CRISPR gene editing. A single infusion permanently reduced LDL cholesterol by 61% in familial hypercholesterolemia.
🚨 Global Oncology Wire • Breaking Medical Regulatory Dispatch Reported by: 24/7 Clinical News Bureau | Peer-Reviewed by: Dr. Marcus […]
Oncology Wire • 24/7 Clinical News Alert | Dispatched from the 247HealthNews Medical Bureau | October 7, 2026 — 09:00 […]
Ophthalmology Wire • 24/7 Clinical News Alert | Dispatched from the International Vision Research Consortium | Published: October 5, 2026 […]
Urgent Cardiology Dispatch • 24/7 Clinical News Bureau | Released: October 5, 2026 AI Urgent Cardiology Wire Breaking Medical Wire […]
Cardiology Wire • 24/7 Clinical News Alert | Dispatched from the American Vascular Research Consortium | Published: October 5, 2026 […]
🔬 Clinical Review • Clinical News & Regulatory Science Monograph Investigated by: Dr. Marcus Vance, MD, FACN | Peer-Reviewed: Clinical […]
🔬 Clinical Review • Clinical News & Regulatory Science Monograph Investigated by: Dr. Marcus Vance, MD, FACN | Peer-Reviewed: Clinical […]